Amos Adler

Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread

Sophia David, Sandra Reuter, Simon R. Harris et al. · Nature Microbiology · 2019 · 818 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study

Hajo Grundmann, Corinna Glasner, Barbara Albiger et al. · The Lancet Infectious Diseases · 2016 · 677 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Mical Paul, George L. Daikos, Emanuele Durante‐Mangoni et al. · The Lancet Infectious Diseases · 2018 · 624 citations

Life Sciences, Infectious Diseases, Microbiology +14

Multidrug-Resistant <i>Candida haemulonii</i> and <i>C. auris</i> , Tel Aviv, Israel

Ronen Ben‐Ami, Judith Berman, Ana Novikov et al. · Emerging infectious diseases · 2017 · 302 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemiological and molecular study

Abiola Olumuyiwa Olaitan, Seydina M. Diene, Marie Kempf et al. · International Journal of Antimicrobial Agents · 2014 · 278 citations

Life Sciences, Infectious Diseases, Microbiology +12